Chief Scientific Officer
Inhibrx, Inc
Brendan Eckelman Ph.D. is a co-founder and the Chief Scientific Officer of Inhibrx, a clinical stage biotherapeutics company. He heads research, overseeing key functional areas spanning early discovery, protein engineering, biotherapeutic development and translational efforts. He has pioneered the innovative suite of therapeutic formats that enable Inhibrx’s differentiated pipeline. He is deeply involved with many operational facets of Inhibrx including business development, partnering, intellectual property and clinical strategy. Brendan spearheaded the formation of Phylaxis Biosciences, an Inhibrx joint venture focused on eosinophilic and mast cell disorders and currently serves on its Scientific Advisory Board. He is an Entrepreneur in Residence for the Office of Innovation and Commercialization at the University of California, San Diego, where he advises founders and start-ups on venture creation and strategy. Prior to Inhibrx, Brendan was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation. He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute and received Ph.D. in Molecular Pathology from the University of California, San Diego School of Medicine. He received his B.S. in Molecular Biology and his M.S. in Biology from UCSD.
